Pernix Therapeutics Announces Restructuring and Integration of the Pernix and Hawthorn Sales Forces
News Jan 25, 2013
The sales force will remain focused on Pediatrics, Primary Care and Gastroenterology.
The Company today also announced that David Becker will resign his position as Chief Financial Officer, due to personal reasons, effective March 31, 2013. The Company has started a search to identify a new Chief Financial Officer. Upon naming a successor, Mr. Becker will serve the Company as a consultant in several areas, including manufacturing, over-the-counter products, and business development.
Cooper Collins, President and CEO of Pernix, said, “We closed the acquisition of Cypress and Hawthorn at the end of December, and we are rapidly making progress in the implementation of our integration plans. In addition, we appreciate the service that David has provided the Company, which included building our OTC product group and completing several key business development transactions that have broadened the scope of our business and expanded our portfolio of branded and generic products.”
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE